



Cambridge Academy
of Therapeutic Sciences

ROYALTY PHARMA

Accelerating Bio-Innovation

Monday 01 April - Wednesday 03 April 2019 | Wellcome Genome Campus, Cambridge, UK



**UNIVERSITY OF
CAMBRIDGE**



Professor Stephen J Toope
Vice-Chancellor,
University of Cambridge

I am delighted to welcome you all to Cambridge, and to the Accelerating Bio-Innovation conference. With such a rich history of discovery and innovation, Cambridge is the perfect location to host this two-day event exploring some of the key challenges currently facing innovators developing new therapies.

The Cambridge cluster is one of the most successful University innovation ecosystems in the world. Recent data shows there are over 4700 knowledge-intensive companies in the Cambridge region, employing more than 60,000 people*. Over 400 of those companies focus specifically on life sciences and healthcare.

As part of its efforts to facilitate interactions with industry, the University recently established the Cambridge Academy of Therapeutic Sciences (CATS). One of its key aims is to foster the pipeline of science and talent underpinning the development of the full spectrum of therapeutics. It offers a portal into the University's very broad therapeutic sciences community, combining expertise across the biomedical, physical, technological and social sciences.

I am grateful to Royalty Pharma, a Foundation Partner in CATS, for sponsoring and co-organising this event, which brings together a powerful mix of award-winning scientists, entrepreneurs, and business leaders, as well as representatives from the NHS and government. I am certain that this rich mix will make for a rewarding and enjoyable conference.

A handwritten signature in black ink, appearing to read 'S. Toope'.

Professor Stephen J Toope
Vice-Chancellor, University of Cambridge



Pablo Legorreta
Founder & Chief Executive Officer,
Royalty Pharma

On behalf of Royalty Pharma, it is my great pleasure to welcome you to the inaugural Accelerating Bio-Innovation conference.

The idea to collaborate with the University of Cambridge on the organization of this exciting new conference was born from our company's long history of working with leading academic institutions. These collaborations have resulted in the funding of a number of important innovations in life sciences.

Just as Cambridge scientists seek discoveries at the frontiers of medical science, Royalty Pharma strives to be at the forefront of creative partnering with academic and for-profit innovators.

By gathering researchers, clinicians, entrepreneurs, representatives of patient associations, capital allocators and policy-makers at the same place for several days, we aim to create a unique and stimulating environment which will inspire us to explore new ways to accelerate bio-innovation.

I thank the Cambridge Academy of Therapeutic Sciences' staff and the members of the steering committee who have made every possible effort to make sure that your participation will be rewarding.

A handwritten signature in black ink, appearing to read 'Pablo Legorreta'.

Pablo Legorreta
Founder & Chief Executive Officer, Royalty Pharma

* www.cambridgeahead.co.uk/cambridge-cluster-map/


About CATS

The Cambridge Academy of Therapeutic Sciences (CATS) is a new platform established at the University of Cambridge, to maximise participation in therapeutic sciences across a very broad range of disciplines, as well as increasing our ability to partner with the pharmaceutical and biotech industry.

Working in partnership, CATS aims to expand the talent pipeline in therapeutic sciences through provision of new teaching and training in the area, including a flagship Master's programme in Therapeutic Sciences (starting October 2019).

CATS is home to the Cambridge Alliance on Medicines Safety, a pre-competitive industry-academia partnership established to build an active research programme around the safety of medicines and invigorate the science underpinning the assessment of toxicology.

Acting as a portal into the University of Cambridge, CATS welcomes interaction with potential industry partners at all levels and provides key support mechanisms to enable research into therapeutics and diagnostics to flourish.



For more information visit www.ats.cam.ac.uk

About Royalty Pharma

Founded in 1996, Royalty Pharma is the industry leader in acquiring pharmaceutical royalties, with over \$16 billion in royalty assets. Royalty Pharma funds innovation in life sciences both directly and indirectly: directly when it partners with life sciences companies to co-develop and co-fund products in late-stage clinical trials, and indirectly when it acquires existing royalty interests from the original innovators (academic institutions, research hospitals, foundations and inventors).

The company's portfolio includes royalty interests in over 40 approved products including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, and Vertex's cystic fibrosis franchise. Royalty Pharma is also a leading investor in pre-approval royalties, having since 2011 invested over \$4 billion in royalties on pre-approval products and committed over \$900 million to direct R&D funding in exchange for royalties.

ROYALTY PHARMA

For more information visit www.royaltypharma.com

Conference steering committee

The Accelerating Bio-Innovation conference has been organised by the Cambridge Academy of Therapeutic Sciences (CATS) in partnership with Royalty Pharma.

We would like to thank our steering committee for their advice and help pulling this exciting programme together:

Professor Chris Abell,
University of Cambridge

Dr Matthias Evers,
McKinsey & Company

Dr Paula Frampton,
CATS, University of Cambridge

Dr Werner Lanthaler, Evotec

Pablo Legorreta, Royalty Pharma

Mark Lewisohn, UBS

Professor Andrew Lo,
Massachusetts Institute of Technology

Professor Chris Lowe,
CATS, University of Cambridge

Osman Mardin, Sardis Capital Ltd

Dr Jim Reddoch, Royalty Pharma

Dr Andy Richards, Cambridge Angels

Dr Iain Thomas, Cambridge Enterprise

Dr Ian Tomlinson,
Apollo Therapeutics and
Stevenage Bioscience Catalyst

Agenda

Monday 01 April

17.00 Registration, check-in and drinks reception

19.00 Pre-dinner lecture:
Promise of gene therapy: a 40-year journey
Professor Jude Samulski, University of North Carolina Gene Therapy Center
Introduced by Dr Jim Reddoch, Royalty Pharma

19.30 Welcome dinner

21.00 After dinner lecture:
Lies your brain tells you: a magician's perspective on how to do better science
Dr Parag Mallick, Stanford University



Accelerating Bio-Innovation

Mon 01 Apr - Wed 03 Apr 2019 | Wellcome Genome Campus, Cambridge, UK

🐦@CambridgeATS | #AccBioInno2019

Wi-Fi

To access the free Wi-Fi simply join the 'Conference Guest' network. Then follow the on screen instructions to register up to five devices for seven days of free Wi-Fi access.

To complete registration you will receive an email, which you will need to validate.

Conference Guest Wi-Fi is available in the Conference Centre, Hall and residential bedrooms.

Tuesday 02 April

08.00 Registration and check-in

09.00 Welcome and opening remarks
Professor Stephen Toope, Vice-Chancellor, University of Cambridge

The Cambridge collaborative environment

Dr Jane Osbourn, AstraZeneca / UK BioIndustry Association

09.30 Plenary 1:
Advent of cellular immunotherapy for cancer

Dr Arie Belldegrun, Allogene
Introduced by Professor Chris Abell, University of Cambridge

The future of medicine:

New therapeutic breakthroughs and challenges

10.00 Session I: Neuroscience:
Progress, challenges, ways forward

Chair: Professor Giovanna Mallucci, University of Cambridge

Development of human antibodies for the treatment and prevention of neurodegenerative diseases

Professor Roger Nitsch, University of Zurich / Neurimmune

Using physical principles to drive drug discovery for protein misfolding diseases

Professor Tuomas Knowles, University of Cambridge

Can artificial intelligence jump-start neuro drug discovery: a case study

Dr Jackie Hunter, BenevolentAI

Modulation of protein degradation in neuro disease

Dr Anker Lundemose, Mission Therapeutics

Enhancing remyelination in multiple sclerosis

Professor Robin Franklin, University of Cambridge

11.15 Coffee break

11.45 Session II: Oncology panel I:
Detection and measurement of cancer: new frontiers

Chair: Dr Leena Das-Young, Guardant

Can we prevent cancer?

Professor Richard Gilbertson, CRUK Cambridge Centre

Detecting cancer through breath biopsy

Billy Boyle, Owlstone Medical

TRACERx: Insights into clinical utility of ctDNA in lung cancer

Dr Chris Abbosh, University College London

Innovation in early detection: a pharma perspective

Dr James Hadfield, AstraZeneca

13.00	Lunch & exhibition Introduced by Dr Michael Anstey, Cambridge Innovation Capital
14.00	Session III: Oncology panel II: How personal should we get? Making choices in cancer immunotherapy Chair: Dr Andrew Allen, Gritstone Oncology <i>Checkpoint inhibitors</i> Professor Sergio Quezada, UCL Cancer Institute / Achilles Therapeutics <i>TCR cell therapy</i> Dr Christian Itin, Autolus <i>Patient selection based on genomics</i> Professor Andrew Biankin, University of Glasgow <i>Bispecific antibodies</i> Dr Christian Rommel, Roche <i>Neoantigen vaccines</i> Dr Andrew Allen, Gritstone Oncology
15.15	Plenary 2: Bicyclic peptides as antibody mimics Professor Sir Greg Winter, University of Cambridge Introduced by Alice Newcombe Ellis, Ahren Innovation Capital
15:45	Coffee break
16:15	Session IV: New approaches to autoimmune disorders Chair: Professor Paul Peter Tak, Flagship Pioneering <i>OX40L blockade to treat chronic inflammatory diseases</i> Dr Sonia Quaratino, Kymab <i>Lupus: Is there a silver lining? An immunologist's perspective</i> Professor David Jayne, University of Cambridge <i>Lupus: Is there a silver lining? A rheumatologist's perspective</i> Dr Vibeke Strand, Stanford University School of Medicine <i>Bioelectronic treatment of rheumatoid arthritis</i> Professor Paul Peter Tak, Flagship Pioneering
17.30	End of day
18:00	Coach transport to Cambridge city centre
19:00	Drinks reception: Master's Lodge, Trinity College, Cambridge
19.30	Dinner: Trinity College, Cambridge Welcome from Professor Sir Greg Winter, Master, Trinity College; Nobel Laureate Featuring St John's College Choir Closing remarks: Professor Andy Neely, Pro-Vice-Chancellor for Enterprise and Business Relations, University of Cambridge

Wednesday 03 April

08.30	Welcome back
08:35	Two-way interview: Cambridge entrepreneurship at industrial scale: X01 and beyond Professor Jim Huntington, University of Cambridge Dr Richard Mason, Foundation Institute for 21st Century Medicine and former CEO XO1 Introduced by Dr Iain Thomas, Cambridge Enterprise
New funding models	
09.15	Session V: Effective translation from the lab Session Chair: Dr Tanisha Carino, Faster Cures <i>Venture philanthropy and the changing role of not-for-profits</i> Dr Preston Campbell, Cystic Fibrosis Foundation <i>Great science = great medicines ... is it really that simple?</i> Dr Ian Tomlinson, Apollo Therapeutics <i>Start Codon – translating amazing research into successful start-ups, the Cambridge way</i> Dr Jason Mellad, Start Codon
10:15	Coffee break
10:45	Plenary 3: Serial entrepreneurship in Cambridge – what I learned Professor Steve Jackson, University of Cambridge Introduced by Dr Andy Richards, Biotechnology Entrepreneur and Business Angel
11.15	Session VI: Bridging the valley of death Session Chair: Dr Matthias Evers, McKinsey <i>Breaking the CRO mould: at-risk target screening & drug discovery</i> Dr Werner Lanthaler, Evotec <i>Blazing a trail in RNAi</i> Dr Yvonne Greenstreet, Alnylam <i>Breaking the business development mould</i> Andrew Dickinson, Gilead <i>Beyond royalties: funding clinical development</i> Pablo Legorreta, Royalty Pharma
12:30	Plenary 4: The digital brain Dr Hermann Hauser, Amadeus Capital Introduced by Professor Chris Abell, University of Cambridge
13:00	Closing remarks Professor Chris Abell, University of Cambridge Pablo Legorreta, Royalty Pharma
13:15	Lunch

Speakers and Chairs

For extended biographies, please visit the conference website: www.ats.cam.ac.uk/bioinno



Chris Abbosh

Tuesday, 11.45

Academic Clinical Fellow, University College London

Dr Chris Abbosh is a senior clinical fellow in medical oncology working on the Cancer Research UK funded lung TRACERx (TRACKing lung Cancer Evolution through treatment Rx) study under the supervision of Professor Charles Swanton at University College London. Chris led the construction of the first TRACERx cell free DNA manuscript focusing on minimal residual disease detection in the adjuvant NSCLC setting which was published in the journal Nature. He is particularly interested in application of circulating tumor DNA (ctDNA) as a tool to stratify risk in adjuvant clinical trials.



Chris Abell

Tuesday, 09.30 / Wednesday, 13.00

Pro-Vice Chancellor for Research, University of Cambridge

A biological chemist, Professor Chis Abell FRS was an undergraduate and graduate at Cambridge, before doing postdoctoral research at Brown University. Today he leads two research teams in the Department of Chemistry at the University of Cambridge and is a Fellow of Christ's College. He was a pioneer in the development of fragment-based approaches to drug discovery, and co-founder of Astex (1999), a world leading company in this area. He has also made major contributions to the development of microfluidic microdroplets as a novel platform for experimental science, and he is a co-founder of Sphere Fluidics (2010) and Aqdot (2013). His interest in the translation of research led him to be a founding director of Cambridge Enterprise. In 2013, he became the first Director of Postdoctoral Affairs at the University of Cambridge, and in January 2016 he was appointed Pro-Vice-Chancellor for Research. He is a Fellow of The Royal Society, The Royal Society of Chemistry and the Academy of Medical Sciences.



Andrew Allen

Tuesday, 14.00

Co-founder, President and CEO, Gritstone Oncology

Dr Andrew Allen, MD, PhD co-founded Gritstone Oncology, Inc. (NASDAQ:GRTS) and has served as President and Chief Executive Officer and a member of the board of directors since August 2015. Prior to Gritstone, in April 2009, he co-founded Clovis Oncology (NASDAQ:CLVS) and served as its executive vice president of clinical and preclinical development and chief medical officer until 2015. Prior to that, he was chief medical officer at Pharmion Corporation from 2006 to 2008 when it was acquired by Celgene. He has also served in clinical development leadership roles at Chiron Corporation and Abbott Laboratories, and worked at McKinsey & Company, where he advised life science companies on strategic issues. He currently serves on the board of directors of Epizyme (NASDAQ:EPZM), TCR2 Therapeutics (NASDAQ:TCRR), Sierra Oncology (NASDAQ:SRRA) and Revitope Oncology (Private) and previously served on the board of directors of Cell Design Labs from November 2015 until its acquisition by Gilead Sciences, Inc. in December 2017. He qualified in medicine at Oxford University and received a PhD in immunology from Imperial College of Science, Technology and Medicine in London.



Michael Anstey

Tuesday, 13.00

Investment Director, Cambridge Innovation Capital

Dr Michael Anstey is an Investment Director specialising in life science investments at Cambridge Innovation Capital. Before joining CIC he was a Principal in the Healthcare Practice Area at The Boston Consulting Group's (BCG) Toronto office. Michael has experience in advising multinational healthcare businesses across North America, Europe, India, and Japan on a broad range of topics, including corporate strategy, sales and marketing, market access, R&D strategy, and M&A. Michael was also co-founder and COO of an early stage biotechnology company focused on developing small molecule drugs that target protein-protein interactions implicated in disease. Prior to BCG, Michael worked in venture capital, where he focused on investing in early stage healthcare and life science businesses. Michael earned his DPhil in Zoology in the field of neurobiology, jointly supervised by professors at the University of Cambridge and the University of Oxford.



Arie Belldegrun

Chairman, Allogene; Former CEO, Kite

Tuesday, 09.30

Dr Arie Belldegrun MD, FACS, is the Executive Chairman and Co-Founder of Allogene. He currently serves as Chairman of Two River Group, UroGen Pharma and Kronos Bio. He is a Co-Founder and Senior Managing Director of Vida Ventures. In 2009, he founded Kite Pharma, a biopharmaceutical company engaged in the development of innovative cancer immunotherapies, and served as Chairman, President and Chief Executive Officer until the acquisition of Kite by Gilead Sciences in October 2017. He is a Professor of Urology, holds the Roy and Carol Doumani Chair in Urologic Oncology, and is Director of the UCLA Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA. He completed his MD at the Hebrew University Hadassah Medical School in Jerusalem, his post-graduate studies in Immunology at the Weizmann Institute of Science, and his residency in urologic surgery at Harvard Medical School. He is certified by the American Board of Urology and is a Fellow of the American College of Surgeons and the American Association of Genitourinary Surgeons.



Andrew Biankin

Regius Chair of Surgery, University of Glasgow

Tuesday, 14.00

Professor Andrew Biankin is the Regius Chair of Surgery at the University of Glasgow, a Cancer Research UK Clinician Scientist, a Wellcome Trust Senior Investigator, a Fellow of the Royal Society of Edinburgh and the Academy of Medical Sciences. He is the Director of the Wolfson Wohl Cancer Research Centre which is focused on precision oncology. He has leadership roles in national and international consortia in cancer genomics and therapeutic development. He has authored over 160 articles in major journals including seminal works on cancer, genomics and precision medicine. His work is currently focused on implementing Precision Oncology Practice in Health Systems internationally.



Billy Boyle

Co-Founder and CEO, Owlstone Medical

Tuesday, 11.45

Billy Boyle is an engineering graduate from University of Cambridge. He is one of the original co-founders of Owlstone Inc, spun out of Cambridge in 2004, which has raised \$28M in investment and won >\$25M in defence contracts. He initially worked with silicon foundries in the design and fabrication of the core microchip technology and is co-inventor on 19 patents. He started to focus on the medical applications of FAIMS technology after his wife, Kate, was diagnosed and later died of colon cancer as a result of a late diagnosis. He worked closely with clinical partners who integrated FAIMS technology across a broad spectrum of clinical trials in cancer, inflammatory disease & infectious disease. He led the process to spin out Owlstone Medical Ltd and became the founding CEO upon the close of a \$7M investment in March 2016. He is also a judge for the Cancer Research UK (CRUK) Pioneer award and a trustee of the Linacre Institute.



Preston Campbell

President and CEO, Cystic Fibrosis Foundation

Wednesday, 09.15

Dr Preston W. Campbell, III, MD, is president and chief executive officer of the Cystic Fibrosis Foundation. He has more than 30 years' experience caring for people with cystic fibrosis and, as executive vice president for medical affairs from 1998 to 2015, led the Foundation's drug development and clinical programs at a time of significant progress in the search for a cure. After earning his medical degree from the University of Virginia Medical School, he spent his residency in a pediatric pulmonology fellowship at Vanderbilt University School of Medicine, serving on the faculty for 12 years and as center director at the Vanderbilt University CF Care Center. He also holds a diploma from the Liverpool School of Tropical Medicine, and early in his career was the director of the Department of Pediatrics at the Centre Medical Beraca, La Pointe, Haiti, where he established a pediatric and public health program.



Tanisha Carino

Executive Director, FasterCures

Wednesday, 09.15

Dr Tanisha Carino joined the Milken Institute in January 2018 as executive director of FasterCures, the center devoted to saving lives and improving the medical research system. Before joining FasterCures she led the U.S. policy function for GSK and prior to that she spent more than a decade with Avalere Health where she founded the Center for Evidence Based Medicine and worked with patients, government, and senior leaders at Fortune 500 companies to maximize opportunities and mitigate challenges related to biomedical research and patient access. She holds a BA in sociology from Emory University in Atlanta and a PhD in health policy from Johns Hopkins University in Baltimore. She is an associate faculty member at the Johns Hopkins Bloomberg School of Public Health and a Fulbright fellow.



Leena Das-Young

General Manager and Chief Lunar Officer, Guardant Health

Tuesday, 11.45

Dr Leena Das-Young is the General Manager and Chief Lunar Officer at Guardant Health responsible for the end-to-end oversight of all work applying Guardant Health's technology and database of more than 100,000 clinical Guardant360 assay toward new applications in early-stage cancer (LUNAR) such as residual disease detection, recurrence monitoring and early detection of cancer. Previously, she was most recently the Vice President & Head of the Late Phase Strategy and Development Group in Pfizer in the Oncology group and was responsible for a portfolio of oncology programs including Ibrance, Xalkori, Talzenna, Besponsa, Sutent, lorlatinib, and others. Prior to her roles in product development, she served in increasingly senior commercial roles responsible for several successful launches in both Pfizer and Bayer. She received her BS and Doctor of Pharmacy degrees from Purdue University.



Andrew Dickinson

Executive Vice President, Corporate Development and Strategy, Gilead

Wednesday, 11.15

Andrew Dickinson joined Gilead in 2016 and is responsible for overseeing the company's corporate development, alliance management, competitive intelligence, and corporate strategy and planning groups. He helped engineer the company's 2017 acquisition of Kite Pharma Inc. Prior to joining Gilead, he served as Global Co-Head of Healthcare Investment Banking for Lazard. At Lazard, he advised on numerous, industry-defining merger and acquisition transactions, as well as many other strategic matters across the biopharmaceutical industry. He received his bachelor's degree in molecular, cellular and developmental biology from the University of Colorado and his law degree from Loyola University Chicago.



Matthias Evers

Senior Partner, McKinsey & Company, Inc.

Wednesday, 11.15

Dr Matthias Evers is a Senior Partner in McKinsey's Hamburg office and co-leads the firm's Global Research & Development work in the Pharmaceutical and Medical Products practice as well as the Global Innovation function. Since joining the firm in 2002, he has engaged with clients in Europe but also in the U.S., China, and India on transforming their organizations to step-up innovation and R&D productivity through deep-rooted transformations. His work often deals with the increasing synergies between advances in biology and (digital) technology and focuses on collaboration across the healthcare innovation ecosystem as well as other industries. He holds a PhD in Chemistry/Biochemistry from the University of Bochum with a focus on Neuroscience. Before his career with McKinsey, he worked as a Research Associate and Postdoctorate at a Center for Molecular Neurobiology in Hamburg. He has authored several articles in the field of bioinformatics and molecular biology.



Robin Franklin

Tuesday, 10.00

Professor of Stem Cell Medicine, Wellcome Trust-MRC Cambridge Stem Cell Institute; Director of the UK MS Society Cambridge Centre for Myelin Repair, University of Cambridge

Professor Robin Franklin is Professor of Stem Cell Medicine at the University of Cambridge School of Clinical Medicine, having previously been Professor of Neuroscience in the University's School of the Biological Sciences. He obtained his undergraduate degrees in Physiology and Veterinary Medicine at the University of London and his PhD in Neuroscience at the University of Cambridge. His main research questions surround how stem cells in the adult brain respond to injury, how they contribute to regeneration, and how they are affected by ageing. He has published over 260 peer-reviewed papers and is internationally recognised as a leader and pioneer in the field of remyelination biology. He was the recipient of the 2017 Barancik International Prize for Research Innovation and is a Fellow of the Academy of Medical Sciences.



Richard Gilbertson

Tuesday, 11.45

Li Ka Shing Chair of Oncology; Head of Department of Oncology; Director CRUK Cancer Centre, University of Cambridge

Professor Richard Gilbertson trained as a pediatric oncologist in the UK before moving in 2000 to St. Jude Children's Research Hospital, USA where he served as Scientific and Comprehensive Cancer Center Director, Executive Vice President and Lillian R. Cannon Endowed Chair. In August 2015, he moved back home to England where he Chairs the Department of Oncology and Directs the CRUK Cambridge Centre at University of Cambridge. His laboratory research is focused on understanding the link between normal development and the origins of cancer, particularly brain tumors.



Yvonne Greenstreet

Wednesday, 11.15

Chief Operating Officer, Alnylam

Dr Yvonne Greenstreet is Chief Operating Officer at Alnylam Pharmaceuticals, a company which is leading the translation of RNA interference into a new class of innovative medicines. She serves on the board of directors of Pacira Pharmaceuticals, Indivior plc, and investment funds managed by Capital Research and Management. Between 2011 and 2013, she was Senior Vice President and Head of Medicines Development at Pfizer and prior to that she spent 18 years with GlaxoSmithKline plc, where she was Senior Vice President and Chief of Strategy for Research and Development. She trained as a physician and earned her medical degree from Leeds University in the UK and her MBA from INSEAD, France.



James Hadfield

Tuesday, 11.45

Director and Principal Diagnostic Scientist, AstraZeneca

Dr James Hadfield leads the search for, and development of, innovative diagnostic assays and technologies for MDx, TDx and PDx working through collaborations and partnering with academia and industry. Previously he led the Genomics Core at University of Cambridge's CRUK Cambridge Institute, he is seconded with Genomics England, and has consulted widely on genomics technologies. He has worked with genomics technologies, especially NGS, for the past 10-15 years. He was awarded PhD at UEA and has co-authored multiple influential papers in cancer genomics including one of the largest genomic studies of Breast Cancer (Nature 2012), some of the first reports of ctDNA liquid biopsy: using amplicons (STM 2012) or exomes (Nature 2013) and developed a sWGS CNV pipeline for exome sequencing (Cell 2016).



Hermann Hauser

Wednesday, 12.30

Co-founder, Amadeus Capital Partners

Serial entrepreneur and co-founder of Amadeus Capital Partners, Dr Hermann Hauser KBE has wide experience in developing and financing companies in the information technology sector. He co-founded a number of high-tech companies including Acorn Computers which spun out ARM, E-trade UK, Virata and Cambridge Network. He co-founded Amadeus Capital Partners in 1997 and has invested in CSR, Solexa, Icera, Xmos and Cambridge Broadband. He is a Fellow of the Royal Society, the Institute of Physics, the Royal Society of Chemistry and the Royal Academy of Engineering, as well as an Honorary Fellow of King's College, Cambridge. In 2001 he was awarded an Honorary CBE for 'innovative service to the UK enterprise sector'. In 2004 he was made a member of the Government's Council for Science and Technology and in 2013 he was made a Distinguished Fellow of BCS, the Chartered Institute for IT. In 2015 Hermann was awarded a KBE for services to Engineering and Industry.



Jackie Hunter

Tuesday, 10.00

Board Director, Benevolent AI and CEO, BenevolentBio

Professor Jackie Hunter CBE is a Board Director for Benevolent AI, a British held AI company which is using AI to augment the research capabilities of drug scientists, radically changing the way R&D is done. She joined the company with over thirty years of experience in the bioscience research sector, working across academia and industry including leading neurology and gastrointestinal drug discovery and early clinical development for GlaxoSmithKline. She was awarded a CBE in the Queen's Birthday Honours list for Services to the Pharmaceutical Industry and was recognized by Forbes Magazine as one of the top 20 Women Advancing AI Research. She is a member of the Biomedical Board for A*Star in Singapore and the Science Advisory Board for the Data Science Institute at Imperial College. She is also a visiting Professor at Imperial College and at St Georges Hospital Medical School.



Jim Huntington

Wednesday, 08.35

Professor of Molecular Haemostasis; CEO, ApcinteX; Department of Haematology, University of Cambridge

Professor Jim Huntington is Professor in Molecular Haemostasis, Department of Haematology, University of Cambridge and principal investigator in the Cambridge Institute for Medical Research. His current research focuses on determining the structures of the molecular engines of blood coagulation, the Xase and prothrombinase complexes, using crystallography and single particle cryo-EM. Over the last few years he has founded several biotech companies, including: XO1 (acquired by Janssen Pharmaceuticals in 2015); SuperX and ReBalance in the field of thrombosis; ApcinteX in haemophilia; Z Factor to treat alpha-1-antitrypsin deficiency; and Cambridge ProteinWorks which provides reagents and services.



Christian Itin

Tuesday, 14.00

CEO and Chairman of the Board of Directors, Autolus

Dr Christian Itin is the Chief Executive Officer and Chairman of the Board of Directors at Autolus, a biopharmaceutical company developing next generation programmed T-cell therapies for the treatment of cancer. Previously he was Chief Executive Officer and Chairman of the Board of Directors of Cytos Biotechnology Ltd, a public biotechnology company that merged with Kuros Biosurgery Holding Ltd. He now serves as a Non-Executive Director of the merged entity, renamed Kuros Biosciences Ltd. He also serves as a Non-Executive Director of the Cambridge-based human antibody company, Kymab Ltd. Prior to joining Cytos, Christian was President and Chief Executive Officer of Micromet Inc., a formerly Nasdaq-listed biopharmaceutical company which was acquired in March 2012 by Amgen Inc. for \$1.2bn. Micromet pioneered T-cell engaging antibodies and with blinatumomab developed the first approved product in this field.



Steve Jackson

Wednesday, 10.45

Professor of Biology and Head of Cancer Research UK Laboratories, Gurdon Institute, University of Cambridge

Professor Steve Jackson FRS, FMedSci is University of Cambridge and Cancer Research UK Professor of Biology, and Head of the Cancer Research UK Laboratories at the Gurdon Institute. His research focuses on defining mechanisms of DNA repair and associated processes, with a view to delivering new biological insights and identifying therapeutic opportunities for cancer and various other diseases. In 1997, he founded KuDOS Pharmaceuticals Ltd (now acquired by AstraZeneca) and more recently, he founded Mission Therapeutics Ltd, to exploit advances in protein ubiquitylation and deubiquitylation, and Adrestia Therapeutics Ltd. He is also a Scientific Advisor for Carrick Therapeutics Ltd and is a Science Partner for Ahren Innovation Capital. He is a fellow of the Royal Society and has received many prizes, including the 2015 Gagna and van Heck Prize for Medicine, the 2016 King Faisal International Prize for Science and the 2016 A.H. Heineken Prize for Medicine.



David Jayne

Tuesday, 16.15

Professor of Clinical Autoimmunity, Department of Medicine, University of Cambridge

Professor David Jayne is Professor of Clinical Autoimmunity at the School of Clinical Medicine, University of Cambridge. His research group conducts clinical trials and biomarker studies in vasculitis and lupus, optimizing the use of current therapies and exploring newer biologic agents. He has defined the current 'standard of care' in ANCA vasculitis and has informed systematic reviews and international consensus management guidelines. He is the Director of the Vasculitis and Lupus Clinic at Addenbrooke's Hospital and is President of the European Vasculitis Society.



Tuomas Knowles

Tuesday, 10.00

Professor of Physical Chemistry and Biophysics, University of Cambridge

Professor Tuomas Knowles studied Biology at the University of Geneva, and Physics at ETH Zurich. He moved to Cambridge in 2004 to work towards his PhD in the Cavendish Laboratory and the Nanoscience Centre. In 2008 he was elected to a Research Fellowship at St John's College, Cambridge, and was then appointed to a University Lectureship in Physical Chemistry in 2010, joining the faculty at the Department of Chemistry in Cambridge. He then successively held a University Readership between 2013 and 2015 and a Professorship since 2015 in the Department of Chemistry. Since 2016 he is Professor of Physical Chemistry and Biophysics in the Department of Chemistry and at the Cavendish Laboratory, and is co-director of the Cambridge Centre for Protein Misfolding Diseases in Cambridge and co-founder of two spin off companies, Wren Therapeutics and Fluidic Analytics.



Werner Lanthaler

Wednesday, 11.15

CEO, Evotec

Dr Werner Lanthaler is the Chief Executive Officer of Evotec, a drug discovery alliance and development partnership company, focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. Previously he was Chief Financial Officer at Intercell AG, which developed from a venture-backed biotechnology company into a global vaccine player. He serves on the Board of Directors of AC Immune SA, is a Non-Executive Director and Chairman of the Audit Committee for arGEN-X SE and is on the Supervisory Board of Topas Therapeutics GmbH. He holds a doctorate in economics from Vienna University, earned his Master's degrees from Harvard University, and holds a degree in Psychology.



Pablo Legorreta

Founder and CEO, Royalty Pharma

Wednesday, 11.15 / Wednesday, 13.00

Pablo Legorreta has over 20 years of experience investing in pharmaceutical royalties, and building and managing a life sciences investment company that is today one of the largest dedicated life sciences investors in the world. Prior to founding Royalty Pharma in 1996, he was an investment banker at Lazard Frères in Paris and New York. He is also a co-founder of Pharmakon Advisors, a provider of debt capital to the life sciences industry. He serves on the Board of Governors of the New York Academy of Sciences, Boards of Trustees of Rockefeller University, Brown University, Hospital for Special Surgery, Pasteur Foundation, Open Medical Institute and Park Avenue Armory. He is the founder and Chairman of Alianza Médica para la Salud, a non-profit dedicated to enhancing the quality of health care in Latin America. He has a degree in industrial engineering from Universidad Iberoamericana in Mexico City.



Anker Lundemose

CEO, Mission Therapeutics

Tuesday, 10.00

Dr Anker Lundemose is the Chief Executive Officer of Mission Therapeutics, a company focused on deubiquitylating enzyme drug discovery and development. He is a serial entrepreneur and founder of several successful biotech companies, and has a broad international pharma, biotech and investor network. He is currently on the board of Inthera Therapeutics and Antag Therapeutics. Prior to joining Mission Therapeutics, he was CEO of Bionor Pharma, and owner and Managing Partner of BioTesch Advice & Consultancy. Previously he was co-founder and CEO of Prosidion, the UK spin-out of OSI Pharmaceuticals' diabetes and obesity assets, which was subsequently reversed into OSI Pharmaceuticals, Inc. At OSI Pharmaceuticals, he was Executive Vice President Corporate Development & Strategy Officer, OSI, New York. Notably he was responsible for the acquisition of the DP-IV patent estate from Probiodrug and involved in the sale of OSI Pharmaceuticals to Astellas Pharma. He is a qualified medical doctor and has a D.MSc and a PhD from the University of Aarhus, Denmark.



Parag Mallick

Associate Professor, Stanford University

Monday, 21.00

Dr Parag Mallick is an Associate Professor at Stanford University. Originally trained as an engineer and biochemist, his research spans computational and experimental systems biology, cancer biology and nanotechnology. He received his undergraduate degree in Computer Science from Washington University in St. Louis. He then obtained his PhD from UCLA in Chemistry & Biochemistry, where he worked with Dr David Eisenberg. He completed Post-Doctoral studies at The Institute for Systems Biology in Seattle, WA with Dr Ruedi Aebersold. Beyond studying fundamental disease mechanisms, his group has been pioneering novel approaches for enabling personalized and predictive medicine. Beyond his academic pursuits, Dr Mallick is a world-renowned magician. A member of the prestigious Magic Castle in Hollywood, Parag has performed for audiences throughout the world.



Giovanna Mallucci

van Geest Professor of Clinical Neurosciences and Associate Director of the UK Dementia Research Institute, University of Cambridge

Tuesday, 10.00

Professor Giovanna Mallucci gained undergraduate degrees in Physiological Sciences and Medicine from the University of Oxford, with clinical training at UCL. She obtained her PhD from London University. Her lab is pioneering interventions targeting common pathways for treatment of dementia. Her work on the role of the UPR in neurodegenerative disease and its pharmacological manipulation has been hailed as "turning point in search for medicines to control and prevent Alzheimer's". She has received numerous national and international awards for her work, including a SciAm50 award and has given many plenary and keynote talks at international conferences. She is an ERC Consolidator Fellow and in 2017 she was elected Fellow of the Academy of Medical Sciences. She is also an Honorary Consultant Neurologist at Addenbrooke's Hospital specialising in dementia.



Richard Mason

Wednesday, 08.35

CEO of Divide & Conquer Ltd; Co-founder of C21Med, The Foundation Institute for 21st Century Medicine

Dr Richard Mason is CEO of Divide & Conquer, a Cambridge based company targeting tunneling nanotubes in cancer, and co-founder of C21Med, an initiative of venture capital firm Medicxi. He served as Head of Johnson & Johnson's London Innovation Centre from October 2015 to April 2018, where he was responsible for innovation within the EMEA region. Prior to joining J&J, Richard was CEO of a venture-backed biotechnology startup, XO1 Ltd. until the company was acquired by J&J in 2015. Prior to that, he was Head of Strategy & BD and member of the Executive Leadership Team at BTG Plc. He was an Executive-in-Residence for Advent Venture Partners where he served as a turnaround CEO for several portfolio companies and prior to that he was a senior leader at Cambridge Antibody Technology. He trained in medicine at the St Bartholomew's Hospital Medical College and worked in clinical practice in internal medicine in the NHS before entering the biotechnology industry. He has a degree in immunology from UCL and an MBA from The Judge Business School, University of Cambridge, where he is an Honorary Fellow in Healthcare Management.



Jason Mellad

Wednesday, 09.15

CEO and Founder, Start Codon

Dr Jason Mellad is a scientist entrepreneur passionate about translating innovative technologies into more effective therapies and better patient outcomes. Prior to founding Start Codon, he was CEO of Cambridge Epigenetix which has developed a proprietary epigenetic biomarker discovery platform for the development of new diagnostic assays and the identification of novel drug targets. Before joining Cambridge Epigenetix, he was a Business Development Manager for Horizon Discovery's diagnostics division and also served as an Associate at Cambridge Enterprise. He was a Marshall Scholar and obtained his PhD in Medicine from the University of Cambridge with a focus on the molecular mechanisms regulating vascular remodeling within coronary artery bypass grafts. He has a BSc (summa cum laude) in Molecular Biology and Chemistry from Tulane University.



Andy Neely

Tuesday, 19.30

Pro Vice Chancellor for Enterprise and Business Relations, University of Cambridge

Professor Andy Neely is Pro-Vice-Chancellor for Enterprise and Business Relations at the University of Cambridge and former Head of the Institute for Manufacturing (IfM). He is a Fellow of Sidney Sussex College, Director of the Centre for Digital Built Britain and Founding Director of the Cambridge Service Alliance. He is widely recognised for his work on the servitization of manufacturing, as well as his work on performance measurement and management. Previously he has held appointments at Cranfield University, London Business School, University of Cambridge, Nottingham University, where he completed his PhD, and British Aerospace. He was Deputy Director of AIM Research – the UK's management research initiative – from 2003 until 2012. He is a Fellow of the Royal Academy of Engineering, a Fellow of the British Academy of Management, a Fellow of the Academy of Social Sciences and a Fellow of the European Operations Management Association.



Alice Newcombe-Ellis

Tuesday, 15.15

Founding and Managing Partner, Ahren Innovation Capital

Alice Newcombe-Ellis has over a decade of investing experience, including at TPG Capital (leading global private equity firm with >\$70BN AUM) and Lansdowne Partners (leading global investment fund with >\$15BN AUM). Her predominant investing focus has been in tech and disruptive healthcare. She holds a Double First Class degree in Mathematics, and Master's in Mathematics/Physics from the University of Cambridge. She was a Fulbright Scholar and a Baker Scholar at Harvard Business School.



Roger M. Nitsch

Tuesday, 10.00

University of Zurich; Founder, President and CEO, Neurimmune

Professor Roger M. Nitsch is the President and CEO of Neurimmune, a Swiss biopharmaceutical company focussing on the development of antibody-based treatments for neurodegenerative diseases. He serves as a part-time Professor at the Institute of Regenerative Medicine at the University of Zurich, is an Executive Organizer of the International Conferences on Alzheimer's and Parkinson's Diseases (AD/PD), a board member of several biotechnology companies, as well as an advisor on the BB Pureos VC fund. Prior to his position at Neurimmune, he served at the University of Zurich, and held research positions at M.I.T. and MGH / Harvard Medical School, Boston, was a Group Leader at the Center for Molecular Neurobiology at the University of Hamburg, Germany. He was a fellow at the Max-Planck Institute for Medical Research in Heidelberg, received an MD from University of Heidelberg Medical School followed by Habilitation in Neurobiochemistry at University of Heidelberg, Germany.



Jane Osbourn

Tuesday, 09.00

Vice-President, Research and Development, AstraZeneca; Chair, UK BiIndustry Association

Dr Jane Osbourn joined MedImmune, formerly Cambridge Antibody Technology (CAT), now the global biologics research and development arm of AstraZeneca, in 1993. An expert in antibody engineering, she has authored many key publications and patents, and made a significant contribution to the discovery and development of a number of marketed drugs and more than 40 clinical candidates. She has worked across many therapy areas and currently leads a global team, based in Gaithersburg US, focused on the development of biosuperior antibody therapies. She is Site Leader for MedImmune's facility in Cambridge UK and chairs the cross-campus leadership team for AstraZeneca in Cambridge. In 2015 she was elected Chair of the BiIndustry Association, and she is also a Director of Babraham Bioscience Technologies and a Director of Cambridge Enterprise.



Sonia Quaratino

Tuesday, 16.15

Chief Medical Officer, Kymab

Dr Sonia Quaratino joined Kymab in 2017, responsible for the clinical strategy and execution of Kymab's first-in-class and innovative programs in immunology and immuno-oncology through pre-clinical and early stage clinical trials. She has over 25 years of experience in industry and academic research with a broad experience as a clinical leader developing both cancer vaccines, small molecules and antibodies for solid and haematological malignancies. Before joining Kymab, she served as Global Clinical Program Leader at Novartis in Basel and prior to that, she was Senior Medical Director in Oncology Early Clinical Development and Advisor in Immunology at Merck Serono in Darmstadt. She received her MD from the University of Palermo School of Medicine, completed her doctorate between the University of Palermo and Imperial College London and served as Professor in Immunology at the University of Southampton.



Sergio Quezada

Tuesday, 14.00

Professor of Cancer Immunology and Immunotherapy, University College London; Co-founder, Achilles Therapeutics

Professor Sergio Quezada earned a PhD from Dartmouth Medical School, where his research focused on the mechanisms for the induction of transplantation tolerance. Following postdoctoral research at Memorial Sloan-Kettering Cancer Center, in 2011 he joined the University College London Cancer Institute as head of the Immune Regulation and Tumor Immunotherapy group. His research group at UCL focuses in the study of the mechanism of action of immune-modulatory antibodies targeting co-inhibitory and co-stimulatory pathways and used as novel anticancer therapies. He holds several patents in the field of cancer immunology, is scientific co-founder of Achilles Therapeutics and scientific advisor to several companies including TUSK Therapeutics, Morphosys and KSQ therapeutics. He has been the recipient of numerous awards and most recently he was awarded with a Cancer Research UK Senior Cancer Research Fellowship.



Andy Richards

Wednesday, 10.45

Biotechnology Entrepreneur and Business Angel

Dr Andy Richards CBE is an entrepreneur and investor with an established track record in founding and scaling up innovative Biotech and Healthtech companies in the UK. He is Chairman of Arecor, Congenica, Abcodia, Closed Loop Medicine and The Babraham Research Campus and is a Director of Silence Therapeutics plc, Ieso Digital Health Ltd, and Owlstone Medical. He is also a director of Cancer Research Technology, a member of CRUK and on the advisory board of the CRUK Early Detection Centre. He is an advisor to several investment funds. He is a Cambridge graduate with a PhD in Chemistry and an early career spanning positions with ICI (now AstraZeneca) and PA Technology. He was a founder and executive director of Chiroscience plc until its merger with Celltech in 1999 and since that time he has founded, invested in and helped to scale more than 25 innovative ventures. He is also a founder member of the Cambridge Angels, and received a CBE for services to life science investment in 2015.



Christian Rommel

Tuesday, 14.00

Global Head of pRED Oncology, Roche

Dr Christian Rommel became Roche's Global Head of pRED Oncology in September 2018 and was previously pRED's Global Head of Oncology Discovery since 2014. He joined Roche from Amgen, where he was most recently Vice President of External Research and Development. He was Chief Scientific Officer of Intellikine from its inception to acquisition by Takeda in December 2011 and before that he was Head of Target Research at Merck Serono in Geneva. He also worked as a scientist in the team of George Yancopoulos at Regeneron Pharmaceuticals, New York. He received his PhD in molecular oncology/signal transduction from the Max Planck Institute in Berlin and the Institute of Medical Virology at the University of Zurich. He has authored more than 70 publications, including papers in Science and Nature, and is an inventor or co-inventor on 18 patents.



Jude Samulski

Monday, 19.00

Founder of the University of North Carolina Gene Therapy Center, Bamboo Therapeutics and Asklepios BioTherapeutics

Dr R. Jude Samulski is a Professor of Pharmacology and the Director of the Gene Therapy Center at UNC. Over 25 years, he has led a team of multiple Principal Investigators developing novel viral vectors and clinical gene therapy programs. In addition to being the lead inventor on over 300 patents in the field of Adeno-associated virus (AAV) vectors & gene therapy, he is a scientific founder of AGCT, Merlin, Asklepios Biopharmaceutical, NanoCor Therapeutics, Chatham Therapeutics, Bamboo Therapeutics, Viragen, and other entities that continue to advance the field of human gene therapy. He served as Vice President of Gene Therapy in Pfizer's Rare Disease Research Unit until February 2018, when he returned full-time to his professorship at UNC. He is a former member of the Recombinant DNA Advisory Committee (RAC), and frequently serves as a gene therapy consultant to the FDA. He received his PhD in Medical Microbiology and Immunology from the University of Florida.



Vibeke Strand

Tuesday, 16.15

Adjunct Clinical Professor, Division of Immunology/Rheumatology, Stanford University School of Medicine; Biopharmaceutical Consultant

Dr Vibeke Strand MD serves as a consultant in clinical research and regulatory affairs to pharmaceutical and biotech companies. She has been a clinical rheumatologist for 35 years – in subspecialty practice in San Francisco, as a clinical investigator and subsequently senior director of clinical research at three pharmaceutical/biotech companies. She has served as Adjunct Clinical Professor, Division of Immunology and Rheumatology at Stanford University since September 2000. Since 1991, she has consulted regarding translation of basic research into rational design of randomized controlled trials, analysis of their results and presentation of novel products for approval to FDA and EMA. She has authored over 400 original publications and is a Fellow of the American College of Physicians (1982), Master of the American College of Rheumatology (2015), member of the Cosmos Club (1994) and its Substitute Board of Managers (2013–2017).



Paul Peter Tak

Tuesday, 16.15

**Venture Partner, Flagship Pioneering;
former Senior Vice President, Chief Immunology Officer and Development Lead, GSK**

Professor Paul Peter Tak MD PhD FMedS is currently CEO of Kintai Therapeutics and Venture Partner at Flagship Pioneering, Professor of Medicine at the Amsterdam University Medical Centre (AMC), Honorary Professor of Rheumatology at Ghent University and Honorary Senior Visiting Fellow at the University of Cambridge. He received his medical degree cum laude from the Free University in Amsterdam and was trained as an internist, rheumatologist and immunologist at Leiden University Medical Center, where he also received his PhD. At GlaxoSmithKline he served as Senior Vice President, Chief Immunology Officer, and Global Development Leader, overseeing the creation of a portfolio of potential medicines for immune-mediated inflammatory diseases and pain. He established ArthroGen b.v., Amsterdam, a biotech company developing intra-articular gene therapy and has been CEO of Tempero Pharmaceuticals. He is also one of the founders and board directors of Sitryx Therapeutics, and serves on the board of directors of Levicept.



Ian Tomlinson

Wednesday, 09.15

Chair of Apollo Therapeutics, Start Codon and Stevenage Bioscience Catalyst

Dr Ian Tomlinson has experience of innovation in both the large and small company environment, along with 11 years spent in academia at the MRC Laboratory of Molecular Biology and as a fellow of Trinity College in Cambridge, UK. In 2000, together with Nobel Laureate Sir Greg Winter, he co-founded Domantis Limited to develop an entirely new class of drugs based on domain antibodies. Domantis was acquired by GSK in 2007 for \$454M. He was at GSK for 9 years where he was SVP, Head of Biopharmaceuticals R&D and Head of Worldwide Business Development. Having left GSK in 2015, he now chairs a number of smaller companies, including the Stevenage Bioscience Catalyst and Apollo Therapeutics, both of which are facilitating the early stage development of a range of life sciences projects.



Stephen Toope

Tuesday, 09.00

Vice Chancellor, University of Cambridge

Professor Stephen J. Toope OC LL.D. became the 346th Vice-Chancellor of the University of Cambridge in October 2017. He joined Cambridge after a distinguished career as a scholar and academic leader. He was Director of the University of Toronto's Munk School of Global Affairs (2015-2017), and before that President and Vice-Chancellor of the University of British Columbia. He served as President of the Pierre Elliott Trudeau Foundation, and as Dean of Law at McGill University. His academic interests are in international law, human rights, international legal theory and international development. He studied History and Literature at Harvard University before earning degrees in common law and civil law at McGill University. He is an alumnus of Trinity College, Cambridge, where he completed a PhD under the supervision of Sir Derek Bowett. Among the distinctions he has received are the Queen Elizabeth II Silver Jubilee Medal (2012), the United Way of Canada President's Award of Distinction (2014) and the John Read Medal of the Canadian Council of International Law (2015). In recognition of his service and accomplishments, in 2015 he was inducted as an Officer of the Order of Canada – one of Canada's highest honours.



Sir Greg Winter

Tuesday, 15.15 / Tuesday, 19.30

Master of Trinity College and 2018 Nobel Prize in Chemistry, University of Cambridge

Professor Sir Gregory Winter is Master of Trinity College, Cambridge and a Fellow of the Royal Society. He is a scientist, inventor and entrepreneur and best known for his research and inventions relating to therapeutic antibodies made at the Medical Research Council's Laboratory of Molecular Biology in Cambridge. He was awarded a share of the Nobel Prize in Chemistry 2018 for his work in making antibodies in phage. He has founded three biotech companies based on his inventions: Cambridge Antibody Technology in 1989 (bought by AstraZeneca), Domantis in 2000 (bought by GSK) and Bicycle Therapeutics in 2009.

Exhibitors

Cambridge Innovation Capital

Cambridge Innovation Capital (CIC) is a venture capital investor in technology and life science businesses. CIC combines a unique relationship with the University of Cambridge with deep financial and industry links to support rapidly growing companies in the Cambridge ecosystem. The company is committed to building leading businesses from brilliant technologies, with the benefit of some of the most influential figures in the sector.



www.cicplc.co.uk / @CambsInnovation

Congenica

Congenica is the provider of the diagnostic decision support platform, Sapia, and associated clinical services, which enable clinicians to interrogate the human genome to identify disease-causing variants. Headquartered in Cambridge, UK, and with a footprint in the US and China, Congenica is born out of pioneering research from the Wellcome Trust Sanger Institute and the NHS. Congenica is a partner for the pivotal Genomics England 100,000 Genomes Project.



www.congenica.com / @Congenica

Microbiotica

Microbiotica was established in 2016 to develop and commercialise ground-breaking research into the role of the human microbiome in health and disease and its application to medicine conducted in the Host-Microbiotica Interactions Laboratory ("HMIL") at the Sanger Institute on the Wellcome Genome Campus in Cambridge, UK. Microbiotica has attracted £12m in equity investment from Cambridge Innovation Capital, IP Group plc and Seventure Partners.



www.microbiotica.com / @MicrobioticaLtd

Bicycle Therapeutics

Bicycle Therapeutics is developing a unique class of chemically synthesised medicines based on its proprietary bicyclic peptide (Bicycle®) product platform to address therapeutic needs unreachable with existing treatment modalities. Bicycle's internal focus is in oncology, where the company is developing targeted cytotoxics (Bicycle Toxin Conjugates®), targeted innate immune activators and T-cell modulators for cancers of high unmet medical need.



www.bicycletherapeutics.com / @Bicycle_tx

LIFNano Therapeutics

LIFNano Therapeutics is a Synthetic Stem Cell company. By exploiting nanotechnology, the uniquely powerful healing properties of "LIF" – a stem cell growth factor – are targeted to treat Multiple Sclerosis (MS), an autoimmune demyelinating disease that attacks the central nervous system. LIFNano™'s threefold values for MS are (i) to repair myelin; (ii) to protect neurons, and (iii) to suppress inflammatory pathogenesis behind the Blood-Brain Barrier.



www.LIFNano.com / @LIFNanoRx

Owlstone Medical

Owlstone Medical has developed Breath Biopsy, a non-invasive way to measure chemicals in breath, for precision medicine, disease detection and exposure research. There are over 1,000 Volatile Organic Compounds (VOCs) in exhaled breath which offers a rich potential source of biomarkers for current researchers and future clinical applications.



www.owlstonemedical.com / @OwlstoneMedical

Elpis BioMed

Command-line access to life_

Our breakthrough OPTi-OX technology combines synthetic and stem cell biology, offering limitless possibilities. It enables a new generation of cell therapies, provides the best human cells for research and drug discovery, and allows the control of advanced synthetic biology circuits for biomanufacturing.



www.elpis.ltd / @ElpisBiomed

Inivata

Inivata is a leader in liquid biopsy. Its InVision® platform, based on pioneering research from the Cancer Research UK Cambridge Institute, unlocks essential genomic information from a simple blood test to transform the care of cancer patients. Its lead product, InVisionFirst™-Lung provides molecular insights that enable clinicians to make more informed treatment decisions for NSCLC patients.



www.inivata.com / @Inivata

Sphere Fluidics

Sphere Fluidics is a Life Sciences company based in Cambridge, UK and New Jersey, USA commercialising single cell analysis systems. Cyto-Mine® is an integrated device accelerating biologics discovery and cell line development by streamlining cell isolation, assaying, sorting, imaging and dispensing into a single automated process, and dramatically reducing costs.



www.spherefluidics.com / @SphereFluidics

Wellcome Genome Campus

The Wellcome Genome Campus is home to some of the world's leading institutes and organisations in the field of genomics and computational biology. As well as undertaking research, organisations on Campus provide bioinformatics resources for the global scientific community, and deliver vital training in genomics and biodata to scientists and clinicians. The Campus is also home to several life science companies, adding to the exceptional and diverse scientific community and uniquely positioning it at the interface of research and industry.

The Campus' purpose is to deliver life-changing science with the reach, scale and imagination necessary to solve some of humanity's greatest health challenges. It was founded with two now world-leading research institutes – the Wellcome Sanger Institute and the EMBL-European Bioinformatics Institute – in the early 1990s at the start of the Human Genome Project, an ambitious global project to sequence the human genome for the first time, and make this data freely available. The Sanger Institute produced around one third of the first human genome sequence over ten years, and the EMBL-EBI developed tools and resources ensuring that this data could be distributed and made publicly accessible.

Since then, the next generation sequencing revolution has enabled genomic data to be produced quickly and cheaply on a previously unimagined scale, changing the model for current and future Campus research. Now home to over 2,000 staff, there are ambitious plans to grow the Campus over the next 25 years, extending its facilities to increase its community of scientific leaders.


Accelerating Bio-Innovation is taking place at the Wellcome Genome Campus Conference Centre, part of which – Hinxton Hall – dates from 1748. The Hinxton Hall estate, first mentioned in records in 1506, was bought by the Wellcome Trust in 1992. Wellcome meticulously restored the Georgian Hall and transformed the old stable block and kitchen garden into a purpose-built conference centre that opened in 1998. The next set of major works were finished in 2015, creating the Conference Centre that you see today. The venue is an integral part of a genomics learning, training and engagement programme called Wellcome Genome Campus Connecting Science. The Conference Centre provides meeting, networking and relaxation spaces conducive to learning and sharing, thus contributing to Connecting Science's mission to enable everyone to explore genomic science and its impact on research, health and society.

Trinity College

Trinity College was founded by Henry VIII in 1546, when he combined two existing colleges, King's Hall and Michaelhouse. Michaelhouse had existed since 1324 and King's Hall had been established by Edward II in 1317. Many of the buildings that we see today were built through the efforts of Thomas Nevile, who became Master of Trinity in 1593, including the main features of Great Court and a large part of the beautiful, cloistered court on the side of the Hall that faces the river.

The College grew rapidly in importance during the century after its foundation, and by 1564 it accounted for a quarter of the total number of resident members of the University. Trinity College undergraduates of the 16th and 17th centuries included Francis Bacon, philosopher and statesman, and the poets George Herbert, Andrew Marvell and John Dryden. Isaac Newton, one of the greatest of all physical scientists, entered the College in 1661 and remained at Trinity until 1696. Byron, Thackeray, and Tennyson were Trinity undergraduates in the early part of the 19th century, and Earl Grey, whose government introduced the great Reform Bill of 1832, is one of Trinity's six Prime Ministers. Famous figures associated with Trinity in the 20th century include James Clerk Maxwell, author of the theory of electromagnetism; J.J. Thomson and Ernest Rutherford, two of the pioneers of atomic physics; the historian G.M. Trevelyan; philosophers Bertrand Russell and Ludwig Wittgenstein; and the novelist Vladimir Nabokov.

Life at Trinity has changed greatly over the centuries but the strong academic tradition has been maintained. In science and economics, for example, Trinity has provided 32 Nobel Prize-winners since they were first awarded in 1901. Today the College is home to around 600 undergraduates, 300 graduates, and over 180 Fellows, and is part of a forward-looking University, renowned for the excellence of its teaching and research.



Delegate list

Chris Abbosh

Medical Oncologist,
University College London

Chris Abell

Pro-Vice-Chancellor for Research,
University of Cambridge

Mateo Aboay

SRC, LML, University of Cambridge

Lilian Alcaraz

Senior Director – New Ventures and
Transactions, Johnson & Johnson
Innovation

Tauhid Ali

VP, Head of TAK-celerator,
Takeda International – UK Branch

Andrew Allen

President & CEO,
Gritstone Oncology

Tim Allsopp

Industry Expert in Residence,
University of Cambridge; Videregen

Steven Altschuler

Managing Director, Ziff Capital
Partners; Board Chair, Spark
Therapeutics

Steve Andrews

Head of Chemistry, ALBORADA
Drug Discovery Institute,
University of Cambridge

Michael Anstey

Investment Director,
Cambridge Innovation Capital plc

Rolf Apweiler

Director, EMBL-EBI

Margaret Ashcroft

Principal Investigator,
University of Cambridge

Rachel Atfield

Commercialisation Manager,
Cambridge Enterprise

Blanca Baez

SVP, Global Head Pharma & Biotech,
Molecular Health GmbH

Trevor Baglin

Venture Partner, Medixi

Sue Bailey

Strategic Partnership and
Early Asset Director, BMS

Arie Beldegrun

Co-Founder & Senior Managing
Director, Vida Ventures

Rebecka Beldegrun

President & CEO, Bellco Capital

Sally Bennett

Investment Manager,
Investment Management

Edward Benthall

Chairman,
Cambridge Innovation Capital

Andrew Biankin

Regius Professor of Surgery,
University of Glasgow

Jeff Bird

Managing Director,
Sutter Hill Ventures

Christina Bird

Physician, Samaritan House

Tom Blundell

Director of Research, Professor
Emeritus, University of Cambridge

Keith Blundy

CEO, Storm Therapeutics

Leszek Borysiewicz

Chairman, Cancer Research UK

Cathy Boucher

Research Facilitator, CATS,
University of Cambridge

Chas Bountra

Pro-Vice Chancellor (Innovation),
University of Oxford

Billy Boyle

CEO, Owlstone Medical

Louise Boyle

Principal investigator,
University of Cambridge

Allan Bradley

CSO, Kymab; Professor,
University of Cambridge

John Bradley

Consultant Renal Physician
and Director of Research,
Cambridge University Hospitals

Kevin Brindle

Professor of Biomedical
Magnetic Resonance,
University of Cambridge

Wendy Britten

Chief Financial Officer, Congenica

Guy Brown

Professor of Cellular Biochemistry,
University of Cambridge

Justin Bryans

Director, Drug Discovery, LifeArc

Clare Bryant

Professor of Innate Immunity,
University of Cambridge

Duncan Budge

Non-Executive Director,
Biopharma Credit plc

Richard Butt

CEO, Apollo Therapeutics

Preston Campbell

President and CEO,
Cystic Fibrosis Foundation

Tanisha Carino

Executive Director, FasterCures

Beverley Carr

VP Business Development, GSK

Sarah Carter

Executive Director, Centre for
Endowment Asset Management,
Judge Business School

Kathryn Chapman

Executive Manager, Milner
Therapeutics Institute

Simon Chell

Director, Discovery Biology,
AstraZeneca

Molly Chiaramonte

SVP, Research & Investments,
Royalty Pharma

David Chiswell

Adviser, Kymab

Victor Christou

CEO, Cambridge Innovation Capital

John Chung

Corporate Development,
Gilead Sciences

Nigel Clark

SVP Business Development,
Kymab

Jim Cleary

Director, RP Management Ireland

Ian Comley

Director, Scientific Partnering
& Alliances – Neuroscience,
AstraZeneca

Ann Connolly

Senior Director, New Ventures &
Transactions, Infectious Disease and
Vaccines, Johnson and Johnson
Innovation

Tim Cox

Director of Research,
University of Cambridge

Terry Coyne

CFO, Royalty Pharma

Nick Crabb

Programme Director – Scientific
Affairs, NICE

Frank Craig

CEO, Sphere Fluidics Limited

Margaret Crotty

CEO, Partnership with Children

Francis Cuss

Proprietor, Promethean Fire LLC

Leena Das-Young

General Manager & Chief Lunar
Officer, Guardant Health

Huw Davies

VP of Global Sales,
Owlstone Medical

Errol de Souza

Executive Chairman,
nLife Therapeutics

Louis DeGennaro

President & CEO,
Leukemia & Lymphoma Society

Andrew Dickinson

Executive Vice President, Gilead

Elroy Dimson

Chair, Centre for Endowment
Asset Management,
Cambridge Judge Business School

Shiva Dustdar

Head of Division Innovation
Finance Advisory, European
Investment Bank

Phil Elstob

Commercialisation Director,
Cambridge Enterprise

Elcin Ergun

President of New Businesses,
Healthcare, EMD Serono Research &
Development Institute, Inc.

Kristine Erwin

Investment Associate, Norgine
Ventures

Inigo Espinosa de los Monteros

Investor, Espinosa de los Monteros
Account

Matthias Evers

Senior Partner,
McKinsey & Company, Inc.

Sam Fazeli

Director of Research,
Bloomberg Intelligence

Brian Ference

Director of Research in
Translational Therapeutics,
University of Cambridge

Mike Fisher

Commercial Director, Oncimmune

Andres Floto

Professor of Respiratory Biology,
University of Cambridge

Alexandria Forbes

CEO, MeiraGTx

Abby Fowden

Head of the School of Biological
Sciences, University of Cambridge

Paula Frampton

Exec Manager of CATS,
University of Cambridge

Robin Franklin

Professor of Stem Cell Medicine,
Wellcome-MRC Cambridge
Stem Cell Institute,
University of Cambridge

Martin Friedman

Managing Member,
Pharmakon Advisors, LP

Jochen Gann

Head of Corporate Finance and
M&A, Boehringer Ingelheim

Danielle Gerlag

Patient Engagement Lead, GSK

Richard Gilbertson

Li Ka Shing Chair of Oncology;
Head of Dept of Oncology;
Director, CRUK Cambridge Centre,
University of Cambridge

Giammaria Giuliani

Chairman, Nogra Pharma

Germano Giuliani

Chairman, Nogra Pharma

Pedro Gonzalez de Cosio

Chief Executive Officer,
Pharmakon Advisors, LP

Arjun Goyal

Co-Founder and Managing
Director, Vida Ventures

Shaun Grady

VP Business Development
Operations, AstraZeneca Ltd

Fabio Grassi

Group leader, Universita della
Svizzera Italiana

Susannah Gray

Executive Vice President – Finance
& Strategy, Royalty Pharma

Yvonne Greenstreet

Chief Operating Officer, Alnylam

David Griffiths-Johnson

Head of Investment and
Engagement, Office for Life
Sciences, Department for Business,
Energy and Industrial Strategy, BEIS

Jeremy Griggs

Industry Expert in Residence,
University of Cambridge; GSK

Joanne Hackett

Chief Commercial Officer,
Genomics England

James Hadfield

Director and Principal Diagnostic
Scientist, Astra Zeneca

Tim Haines

Managing Partner, Abingworth

Thomas Hanke

Head of academic BRIDGE efforts,
Evotec

Helen Harrison

Group Leader – Assay Biology,
Bicycle Therapeutics

Hermann Hauser

Co-Founder and Partner,
Amadeus Capital Partners

Tony Hickson

Chief Business Officer,
Cancer Research UK (CRUK)

Victoria Higgins

Senior Director/Cambridge Alliance
Lead, GSK

Andrew Hindman

Chief Business Officer,
Acorda Therapeutics, Inc.

Linda Hindmarsh

Senior Associate Director,
Development and Alumni
Relations, University of Cambridge

Jackie Hunter

CEO, Benevolent Bio

Jim Huntington

Professor of Molecular Haemostasis,
University of Cambridge

Marguerite Hutchinson

VP, Business Development & Legal
Affairs, Plexixikon Inc.

Marko Hyvonen

Research Group Head,
University of Cambridge

Adrian Ibrahim

Head Of Business Development
and Technology Transfer,
Wellcome Sanger Institute

Christian Itin

CEO and Chairman, Autolus
Therapeutics

Laura Itzhaki

Professor, University of Cambridge;
CSO, Polyprox Therapeutics

Sabine Jaccaud

Communications Director,
AstraZeneca

Steve Jackson

Frederick James Quick Professor of
Biology, University of Cambridge

David Jayne

Professor of Clinical Autoimmunity,
University of Cambridge

Harren Jhotti

CEO & President,
Astex Pharmaceuticals

Joanne Jones

PI/Honorary Consultant Neurologist,
University of Cambridge

Derek Jones

CEO, Babraham Research Campus

Oguzhan Karakas

University Senior Lecturer in
Finance, Cambridge Judge Business
School

Gary Keegan

Development Director –
Cambridge University Health
Partners, University of Cambridge
Development and Alumni Relations
Office

Karen Kennedy

Director, Strategic Partnerships
Office, University of Cambridge

Walid Khaled

Group leader,
University of Cambridge

Rachna Khosla

Vice President, Business
Development, Amgen

Helen Kim

Director, Technology Licensing,
Amgen

Tuomas Knowles


Professor, University of Cambridge

Thomas Korossy CEO, Paris Capital Advisors Ltd, Paris Capital Advisors	Osman Mardin Managing Director, Sardis	Greg Norden Director, Royalty Pharma	Christian Rommel Global Head Oncology, Roche	Michael Sutcliffe Professor of Biomedical Engineering, University of Cambridge
James Körössy Imperial College London	Anita Marguerie de Rotrou Head of Office for Translational Research, University of Cambridge	Jeremy O'Hanlon Corporate Development, Gilead Sciences	Evis Sala Professor of Oncological Imaging, University of Cambridge	Emma Sutcliffe Head, Patient Engagement, NexGen Healthcare
Mark Kotter Principal Investigator, University of Cambridge; CEO, ElpisBiomed	Christine Martin Investment Manager, Cambridge Enterprise	Colin Orford Sr VP & Head, Drug Development Services, ICON Clinical Research	Shamith Samarajiva Group Leader, University of Cambridge	Paul Peter Tak President and CEO, Kintai Therapeutics
Brienne Kugler VP, Royalty Pharma	Steve Martin VP, Biopharm Discovery, GSK	Jane Osbourn VP R&D, AstraZeneca	R. Jude Samulski Professor, Department of Pharmacology, University of North Carolina	Dave Tapolczay CEO, St George Street Capital
Angela Kukula Director of Enterprise, ICR	Richard Mason Co-founder, C21Med	Richard Parkes Equity analyst, Deutsche Bank	Hitesh Sangane Head of Emerging Innovations, AstraZeneca	Iain Thomas Head of Life Science, Cambridge Enterprise
Madeline Lancaster Group Leader, MRC LMB	Sharon Mates Chairman and Chief Executive Officer, Intra-Cellular Therapies	Terry Parlett Commercialisation Director, Cambridge Enterprise	Helen Savage Deputy Head of Clinical Services & Product Manager, Congenica	Claire Thompson CEO, Agility Health Tech
Werner Lanthaler CEO, Evotec	Patrick Maxwell Regius Professor of Physic and Head of School of Clinical Medicine, University of Cambridge	Vibhuti Patel Head of Bioscience Impact Team, University of Cambridge	Stephen Sawcer Principal Investigator, University of Cambridge	Craig Tipple Clinical Director, Cambridge Unit, GSK
Araminta Ledger Director of Campus Development, Cambridge University Health Partners	Paul McBarron EVP, Finance & COO, Cyclacel Pharmaceuticals, Inc.	Sir Keith Peters Advisory, University of Cambridge/ Francis Crick Institute	Henrik Schliemann Managing Partner, PMB Capital	Jonathan Tobin Investment Director, Aris Bioscience
Pablo Legorreta Founder and Chief Executive, Royalty Pharma	Tom McCarthy Executive Chairman, Grey Wolf Therapeutics Ltd	Anna Philpott Professor, University of Cambridge	Arndt Schottelius Interim CEO and EVP, Head of R&D, Kymab	Ian Tomlinson Chairman, Apollo Therapeutics
Brandon Lewis Head of Corporate Strategy, Kymab Ltd	Will McEwan Sir Henry Dale Fellow, University of Cambridge	Stefan Platz Senior Vice President Drug Safety & Metabolism, AstraZeneca	Gary Sclar VP, Dana-Farber Innovation, Dana-Farber Cancer Institute	Stephen Toope Vice-Chancellor, University of Cambridge
Mark Lewisohn Group Managing Director, UBS	John McKinley Chairman, Caldwell Capital Limited	Thomas Pompidou Founding Partner, Marker	Enrique Senior President, Allen & Co.	Chris Torrance CEO, PhoreMost Ltd
John Liddicoat Senior Research Associate, University of Cambridge	Jason Mellad CEO, Start Codon	Stanislas Poniatowski Director, Quilvest Switzerland Ltd	Eva Serra Pre-Registration Clinical Scientist & Product Manager, Congenica	Olivia Tournay Flatto President, The Pershing Square Foundation
George Lloyd Executive Vice President, Investments and General Counsel, Royalty Pharma	Su Metcalfe Founder and CEO, LIFNano Therapeutics Ltd	Chris Powell Vice President, Translational Medicine & Pathobiology, GSK	Helena Shaskevich Associate, Royalty Pharma	Marshall Urist SVP, Research & Investments, Royalty Pharma
Chris Lowe Director, Cambridge Academy of Therapeutic Sciences (CATS), University of Cambridge	Sheila Mikhail Chief Executive Officer, Asklepios BioPharmaceutical, Inc.	Krishna Prasad Expert /Group Manager, MHRA, DoH	Jesse Shefferman CEO, ArTara Therapeutics	Rene van der Merwe VP Clinical Development, Medimmune
Jan Löwe Director, MRC Laboratory of Molecular Biology	Tim Minshall Head of Institute for Manufacturing, University of Cambridge	Gabor Purman Senior Account Director, NexGen Healthcare Communications	Jeremy Sillem Chairman, BioPharma Credit PLC	Jana Voigt Director & Founder, CAM Innovations Ltd
Malcolm Lowe-Lauri Executive Director, Cambridge University Health Partners	Sohaib Mir Associate, Cambridge Innovation Capital	Sonia Quaratino CMO, Kymab Ltd	Bill Skach Senior VP of Research Affairs, Cystic Fibrosis Foundation	Friedrich von Bohlen und Halbach CEO, Molecular Health GmbH
Anker Lundemose Chief Executive Officer, Mission Therapeutics	Eric Miska Herchel Smith Professor of Molecular Genetics, University of Cambridge	Sergio Quezada Professor of Cancer Immunology and Immunotherapy, University College London	John Skidmore Chief Scientific Officer, ALBORADA Drug Discovery Institute, University of Cambridge	Alexander von Perfall VP, IR, Royalty Pharma
Brendan Luu Head of Oncology Business Development, EMD Serono	Tim Mitchell Founder & CEO, Sareum Holdings	Greg Raskin Vice President, Technology Development, Memorial Sloan Kettering Cancer Center	Carmen Smith Administrator, CATS, University of Cambridge	Andrea Walker Research Facilitator, CATS, University of Cambridge
Jon Lyon Industry Expert in Residence, University of Cambridge; GSK	Padraig Mulcahy Education Programme Manager, CATS, University of Cambridge	Jim Reddoch EVP, Research & New Investments, Royalty Pharma	Mike Snowden Senior Vice President, Discovery Sciences, AstraZeneca	Malcolm Weir Executive VP & Chief R&D Officer, Sosei Heptares
John Macdonald Vice President, Venture & Financial Alliances, ICON Clinical Research	Martin Murphy CEO, Syncona	David Rees CSO, Astex	David Spring Principal Investigator, University of Cambridge	Andreas Wicki CEO, HBM Healthcare Investments AG
Aditya Malkar Product Specialist - Business Development, Owlstone Medical	Mike Murphy Professor, University of Cambridge	Louise Rich Head of Investor Relations and Corporate Communications, Cambridge Innovation Capital	Jagjit Srail Head Centre for International Manufacturing, University of Cambridge	Anna Williamson Business Development, Genentech/Roche
George Malliaras Prince Philip Professor of Technology, University of Cambridge	Andy Neely Pro-Vice-Chancellor for Enterprise and Business Relations, University of Cambridge	Gregory Winter Professor / Investigator, University of Cambridge	Steven Wilson Head of Innovation, Cambridgeshire & Peterborough Combined Authority	Gregory Winter Master, Trinity College, University of Cambridge
Parag Mallick Associate Professor, Stanford University	Alice Newcombe-Ellis Founding and Managing Partner, Ahren Innovation Capital	Andy Richards Biotechnology Entrepreneur and Business Angel; Chairman, Babraham Research Campus	Peter St George-Hyslop CEO, HBM Healthcare Investments AG	Ian Woo Managing Director, C-Bridge Capital
Giovanna Mallucci Director UK Dementia Research Institute, University of Cambridge	Pete Newham Head of Oncology Safety, AstraZeneca	Duncan Richards Professor of Clinical Therapeutics, University of Oxford	Kristin Stafford CAO, Royalty Pharma	Amanda Wooding Deputy Head of Life Sciences, Cambridge Enterprise
Rob Marchmont Vice-President of Sales and Marketing, Sphere Fluidics	Serena Nik-Zainal CRUK Advanced Clinician Scientist, University of Cambridge	Rory Riggs Chairman, Royalty Pharma	Kai Stoeber VP, Global Innovation, Shionogi	Rob Woodman Senior Partner, Takeda
	Roger Nitsch President & CEO Neurimmune AG; Professor University of Zurich	Gary Robinson Investment Manager, Baillie Gifford	Vibeke Strand Adjunct Clinical Professor and Biopharmaceutical Consultant, Division of Immunology/ Rheumatology, Stanford University	Qun Yang COO, Biorbyt Ltd
		Mike Romanos CEO, Microbiotica Limited		Peony Yu Chief Medical Officer, Fibrogen



Cambridge Academy
of Therapeutic Sciences

ROYALTY PHARMA



UNIVERSITY OF
CAMBRIDGE